198 related articles for article (PubMed ID: 35486638)
21. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
Xu J; Xie L; Sun X; Liu K; Liang X; Cai Z; Tang X; Guo W
Clin Cancer Res; 2023 Mar; 29(6):1040-1046. PubMed ID: 36622702
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
[TBL] [Abstract][Full Text] [Related]
23. Second-line lurbinectedin as a new treatment option for small-cell lung cancer: Preliminary results in real-clinical practice.
Toublanc AC; Guecamburu M; Veillon R; Rosellini P; Girodet PO; Zysman M
Thorac Cancer; 2022 Aug; 13(15):2248-2252. PubMed ID: 35715960
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group.
DuBois SG; Krailo MD; Lessnick SL; Smith R; Chen Z; Marina N; Grier HE; Stegmaier K;
Pediatr Blood Cancer; 2009 Mar; 52(3):324-7. PubMed ID: 18989890
[TBL] [Abstract][Full Text] [Related]
25. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gaillard S; Oaknin A; Ray-Coquard I; Vergote I; Scambia G; Colombo N; Fernandez C; Alfaro V; Kahatt C; Nieto A; Zeaiter A; Aracil M; Vidal L; Pardo-Burdalo B; Papai Z; Kristeleit R; O'Malley DM; Benjamin I; Pautier P; Lorusso D
Gynecol Oncol; 2021 Nov; 163(2):237-245. PubMed ID: 34521554
[TBL] [Abstract][Full Text] [Related]
26. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Wang BC; Xiao BY; Lin GH
BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
[TBL] [Abstract][Full Text] [Related]
27. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
[TBL] [Abstract][Full Text] [Related]
29. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
30. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
31. Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer.
Fernández-Teruel C; Fudio S; Lubomirov R
Cancer Chemother Pharmacol; 2022 May; 89(5):585-594. PubMed ID: 34739582
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.
DuBois SG; Krailo MD; Glade-Bender J; Buxton A; Laack N; Randall RL; Chen HX; Seibel NL; Boron M; Terezakis S; Hill-Kayser C; Hayes A; Reid JM; Teot L; Rakheja D; Womer R; Arndt C; Lessnick SL; Crompton BD; Kolb EA; Daldrup-Link H; Eutsler E; Reed DR; Janeway KA; Gorlick RG
J Clin Oncol; 2023 Apr; 41(11):2098-2107. PubMed ID: 36669140
[TBL] [Abstract][Full Text] [Related]
33. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Peters S; Trigo J; Besse B; Moreno V; Navarro A; Eugenia Olmedo M; Paz-Ares L; Grohé C; Antonio Lopez-Vilariño J; Fernández C; Kahatt C; Alfaro V; Nieto A; Zeaiter A; Subbiah V
Lung Cancer; 2024 Feb; 188():107448. PubMed ID: 38198859
[TBL] [Abstract][Full Text] [Related]
34. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Xu J; Xie L; Sun X; Liu K; Tang X; Yan T; Yang R; Guo W; Gu J
Oncologist; 2021 Jul; 26(7):e1256-e1262. PubMed ID: 33611805
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer.
Awada AH; Boni V; Moreno V; Aftimos P; Kahatt C; Luepke-Estefan XE; Siguero M; Fernandez-Teruel C; Cullell-Young M; Tabernero J
ESMO Open; 2022 Dec; 7(6):100651. PubMed ID: 36455505
[TBL] [Abstract][Full Text] [Related]
36. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Chugh R; Ballman KV; Helman LJ; Patel S; Whelan JS; Widemann B; Lu Y; Hawkins DS; Mascarenhas L; Glod JW; Ji J; Zhang Y; Reinke D; Strauss SJ
Cancer; 2021 Apr; 127(8):1301-1310. PubMed ID: 33289920
[TBL] [Abstract][Full Text] [Related]
37. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
38. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.
Anderson PM; Bielack SS; Gorlick RG; Skubitz K; Daw NC; Herzog CE; Monge OR; Lassaletta A; Boldrini E; Pápai Z; Rubino J; Pathiraja K; Hille DA; Ayers M; Yao SL; Nebozhyn M; Lu B; Mauro D
Pediatr Blood Cancer; 2016 Oct; 63(10):1761-70. PubMed ID: 27362300
[TBL] [Abstract][Full Text] [Related]
40. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]